Jayakumar Patil, MD
Psychiatry · Bedford, NHNPI 1144339417
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 264 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,133 and has fallen 61.7% since, to $1,199 in 2025. Among psychiatry clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $29.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$629
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$621
- Teva Pharmaceuticals USA, Inc.$590
- Lundbeck LLC$539
- plus $3K from 17 others
What the payments were for
- Food & beverage$7,72399%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 64 | $1,449 |
| Johnson & Johnson | 22 | $1,285 |
| Otsuka America Pharmaceutical, Inc. | 31 | $629 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $621 |
| Teva Pharmaceuticals USA, Inc. | 12 | $590 |
| Lundbeck LLC | 27 | $539 |
| Jazz Pharmaceuticals Inc. | 20 | $489 |
| Ironshore Pharmaceuticals Inc. | 12 | $368 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $364 |
| Axsome Therapeutics, Inc. | 3 | $228 |
| Sunovion Pharmaceuticals Inc. | 8 | $216 |
| Corium, LLC | 7 | $190 |
| Vanda Pharmaceuticals Inc. | 3 | $161 |
| Shire North American Group Inc | 9 | $158 |
| Alkermes, Inc. | 3 | $105 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $98 |
| Avanir Pharmaceuticals, Inc. | 3 | $61 |
| Pfizer | 4 | $57 |
| Biogen | 2 | $55 |
| Neos Therapeutics, LP | 2 | $36 |
| Neurocrine Biosciences, Inc. | 2 | $32 |
| Alfasigma USA, Inc. | 1 | $20 |
| Noven Therapeutics, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,768 in reported general payments places this provider in the 90th percentile of 166 psychiatry providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 18 | $26,793 |
| TrintellixVortioxetine Hydrobromide | 20 | $14,229 |
| AdderallDextroamphetamine/Amphetamine | 12 | $7,593 |
| Lisdexamfetamine Dimesylate | 17 | $4,527 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 31 | $4,110 |
| Bupropion XlBupropion Hcl | 89 | $2,980 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 86 | $2,900 |
| Clorazepate Dipotassium | 18 | $2,488 |
| Duloxetine Hcl | 50 | $1,571 |
| Clonazepam | 170 | $1,451 |
| Oxazepam | 11 | $1,384 |
| Hydroxyzine Hcl | 31 | $1,004 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $1,003 |
| Methylphenidate Hcl | 26 | $979 |
| Methylphenidate Hcl Er (Cd)Methylphenidate Hcl | 13 | $935 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $629 | $26,79318 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall | $364 | $21,82232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 166 psychiatry providers in New Hampshire.
Other psychiatry in Bedford
- John MillerExeter$2.7M
- Stephen EllenNashua$1.4M
- Michael McNamaraManchester$754K
- Kenneth BrownBrentwood$94K
- Janet CarellaManchester$82K
- Robert CotesLebanon$64K
- Quentin TurnbullManchester$25K
- Paul LidstromLittleton$14K
- Juliette MadanLebanon$13K
- Wassfy HannaPortsmouth$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.